PreveCeutical Confirms No Material Change
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), at the request of the Investment Industry Regulatory Organization of Canada (IIROC), confirms that its management is not aware of any undisclosed corporate development or material change to the Company or its operations that would account for the recent increase in market activity. About PreveCeutical PreveCeutical is a...
2018-09-18 4:23 PM EDT
PreveCeutical Develops Proprietary Extraction Protocol for Medical Cannabinoids to be Used with the Sol-gel Drug Delivery Program
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, during its soluble gel ("Sol-gel") drug delivery research and development program (the "Sol-gel Program"), it has successfully optimised the conditions for extracting cannabinoids from one of its cannabis strains and developed a proprietary method for the accurate and precise quantification of cannabinoids...
2018-09-04 9:30 AM EDT
PreveCeutical Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - August 22, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update on the Company's progress in its ongoing corporate initiatives. PreveCeutical has recently reached several milestones as it continues to execute its strategy to become a global preventive healthcare company. These milestones include: entering into a natural health product licensing agreement (the...
2018-08-22 9:00 AM EDT
PreveCeutical Signs Agreement with Asterion Cannabis Inc. to License Natural Health Products and Engages Monster Media, LLC to Provide Investor Relations Services
Vancouver, British Columbia--(Newsfile Corp. - August 15, 2018) - PreveCeutical Medical Inc. ("PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), and Asterion Cannabis Inc. ("Asterion") announce that they have signed an agreement (the "Licensing Agreement"), whereby Asterion has granted to PreveCeutical a worldwide licence to use, manufacture, distribute and sell three Health Canada
2018-08-15 9:30 AM EDT
PreveCeutical Announces First Cannabis Product for Treatment of Anxiety
Vancouver, British Columbia--(Newsfile Corp. - August 8, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the first product development program of the Company's newly created medicinal cannabis division is focusing on the development of cannabinoids as a preventive treatment for anxiety disorders using PreveCeutical's nasal delivery, sustained release, Sol-gel ("Sol-gel") delivery platform. For further information on the...
2018-08-08 9:30 AM EDT
PreveCeutical Provides Update on Second Phase of Scorpion Venom-Derived Peptide Program
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update on its three phase, scorpion venom-derived peptide research and development program (the "Program"), which consists of identifying, extracting and sequencing peptides and proteins isolated from Caribbean Blue Scorpion venom, which are a highly complex mixture of peptides, enzymes, mucoproteins, free...
2018-07-31 9:30 AM EDT
PreveCeutical Announces Launch of Cannabis Division
Vancouver, British Columbia--(Newsfile Corp. - July 24, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, in keeping with the Company's vision of becoming a global preventive healthcare company, PreveCeutical has launched a medicinal cannabis division (the "Cannabis Division"). The Cannabis Division will be responsible for bringing an array of high-quality, medicinal cannabis-based products to market, and overseeing...
2018-07-24 9:30 AM EDT
PreveCeutical Provides Update on Sol-gel Drug Delivery Program
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update on the soluble gel ("Sol-gel") drug delivery research and development program (the "Sol-gel Program"), that involves testing an array of cannabis strains for the development and commercialisation of cannabinoid-based Sol-gels. The Company's Sol-gel Program uses five distinct Cannabis sativa L....
2018-07-11 9:00 AM EDT
PreveCeutical Retains Link Media LLC to Provide Marketing Services
Vancouver, British Columbia--(Newsfile Corp. - July 10, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announced that it has retained Link Media LLC ("Link Media") to provide communications and market awareness services to the Company, aimed at maintaining and building the profile of PreveCeutical among existing and potential investors. Pursuant to its consulting agreement with PreveCeutical, Link Media will arrange and coordinate...
2018-07-10 12:05 AM EDT
PreveCeutical Announces the Closing of Oversubscribed Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces the closing of its oversubscribed non-brokered private placement financing previously announced April 9, 2018 (the "Financing"). A total of 130,799,750 units (the "Units") were issued under the Financing at a price of $0.05 per Unit for gross proceeds of $6,539,987.50. Each Unit consists of one common share in the capital...
2018-06-29 10:00 AM EDT
PreveCeutical Announces Oversubscribed Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that based on subscriptions received to date, the Company expects that its $4,000,000 non-brokered private placement (the "Offering") of units at $0.05 (post-forward stock split) announced on April 9, 2018, will be oversubscribed due to higher than expected investor interest. The Company now expects that the Offering will...
2018-06-25 4:01 PM EDT
PreveCeutical Amends Terms of Warrants to Extend Expiry Date
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it will be amending the terms of 20,280,000 (4,076,000 pre-forward stock split) common share purchase warrants (each, a "Warrant") previously issued pursuant to a non-brokered private placement that closed on June 29, 2017. The Warrants were originally exercisable by the holder at a price of $1.00 per common share in...
2018-06-08 5:00 PM EDT
PreveCeutical Engages Stadnyk & Partners to Provide Market Awareness and Strategic Advisory Services
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that is has entered into an agreement with Stadnyk & Partners, whereby it has agreed to engage Stadnyk & Partners to provide strategic advisory services to the Company. The agreement provides that Stadnyk & Partners will provide market awareness services to the Company during the term of the agreement, for which the...
2018-06-05 3:05 AM EDT
PreveCeutical Provides Update on Forward Stock Split
Vancouver, British Columbia--(Newsfile Corp. - May 23, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to shareholder approval of a forward stock split (the "Stock Split") of the Company's issued and outstanding common shares (each, a "Share") on the basis of five new Shares for each one existing Share (see news release dated May 17, 2018), the Company's Shares have commenced trading today on the Canadian...
2018-05-23 12:37 PM EDT
PreveCeutical Shareholders Approve Five-for-One Forward Stock Split
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that at its annual general and special meeting of Shareholders held on May 14, 2018, shareholders passed a special resolution approving the proposed forward stock split of the Company's issued and outstanding common shares on the basis of five new common shares for each one existing common share (the "Stock Split"). The...
2018-05-17 9:30 AM EDT
PreveCeutical Medical: Second Shipment of Dried Cannabis Materials Arrives at the Pharmacy Australia Centre of Excellence
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the arrival of the second shipment of dried cannabis materials at the Pharmacy Australia Centre of Excellence ("PACE") at the University of Queensland ("UQ"). The shipment came from PreveCeutical's partner, a Canadian licensed producer. The cannabis materials will be used for PreveCeutical's soluble gel ("Sol-gel") drug...
2018-05-14 9:30 AM EDT
PreveCeutical Signs Non-Disclosure Agreement with World Leading Specialized Drug Delivery Device Manufacture
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has signed a non-disclosure agreement (the "NDA") with a globally recognized, innovative drug delivery device manufacturer (the "Manufacturer"). The NDA will allow the Company to enter into discussions with the Manufacturer for the supply of spray devices for use in the Company's soluble gel ("Sol‑gel") drug...
2018-05-07 9:30 AM EDT
PreveCeutical Enters into Credit Facility Agreement; Amends Credit Facility Agreement
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that it has entered into a $700,000 credit facility agreement with the Company's former President and director, Kimberly Van Deventer, and amends and increases a credit facility agreement with Ms. Van Deventer and the Company's Chief Executive Officer, President and director, Stephen Van Deventer (collectively, the...
2018-04-27 9:20 PM EDT
PreveCeutical Announces Non-Brokered Private Placement Announces 2018 Annual General and Special Meeting Date
Vancouver, British Columbia--(Newsfile Corp. - April 9, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces a non-brokered private placement of up to 16 million units (each, a "Unit") at the price of $0.25 per Unit for aggregate gross proceeds of up to CAD$4,000,000 (the "Financing"). Each Unit will consist of one common share of the Company (each, a "Share") and one warrant (each, a "Warrant"), with each Warrant entitling the...
2018-04-09 10:57 AM EDT
PreveCeutical Medical Inc. Now Accepts Bitcoin as a Payment Method
Vancouver, British Columbia--(Newsfile Corp. - January 15, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the Company will now accept Bitcoin as payment for the Company's CELLB9® product. The Company will process Bitcoin payments through BitPay, Inc. Bitcoin is a cryptocurrency which was introduced in 2009. Since its introduction, Bicton has gained rapid popularity and entered the mainstream as the...
2018-01-15 3:05 AM EST